tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

TherapeuticsMD reports Q2 EPS 5c vs. (9c) last year

License revenue, primarily from the Mayne License Agreement, totaled $1.0 million for the second quarter of 2025, an increase of $0.7 million, compared to $234 thousand in license revenue for the second quarter of 2024. The increase is primarily attributable to changes in sales of licensed products.

Meet Your ETF AI Analyst

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1